LymphedemaV1, PascalFrancis, Corpus, bibRecord, 000196

Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema

Identifieur interne : 000196 ( PascalFrancis/Corpus ); précédent : 000195; suivant : 000197

Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema

Auteurs : Markku L Hteenvuo ; Krista Honkonen ; Tomi Tervala ; Tuomas Tammela ; Erkki Suominen ; Johanna L Hteenvuo ; Ivana Kholova ; Kari Alitalo ; Seppo Yl Herttuala ; Anne Saaristo

Source :

Circulation : (New York, N.Y.) [ 0009-7322 ] ; 2011.

RBID : Pascal:11-0119641

Descripteurs français

Pascal (Inist)
- Lymphoedème, Pathologie de l'appareil circulatoire, Facteur croissance, Traitement, Système autologue, Ganglion lymphatique, Système lymphatique.

English descriptors

KwdEn :
- Autologous system, Cardiovascular disease, Growth factor, Lymph node, Lymphatic system, Lymphedema, Treatment.

Abstract

Background-Lymphedema after surgery, infection, or radiation therapy is a common and often incurable problem. Application of lymphangiogenic growth factors has been shown to induce lymphangiogenesis and to reduce tissue edema. The therapeutic effect of autologous lymph node transfer combined with adenoviral growth factor expression was evaluated in a newly established porcine model of limb lymphedema. Methods and Results-The lymphatic vasculature was destroyed within a 3-cm radius around an inguinal lymph node. Lymph node grafts and adenovirally (Ad) delivered vascular endothelial growth factor (VEGF)-C (n=5) or VEGF-D (n=9) were used to reconstruct the lymphatic network in the inguinal area; AdLacZ (β-galactosidase; n=5) served as a control. Both growth factors induced robust growth of new lymphatic vessels in the defect area, and postoperative lymphatic drainage was significantly improved in the VEGF-C/D-treated pigs compared with controls. The structure of the transferred lymph nodes was best preserved in the VEGF-C-treated pigs. Interestingly, VEGF-D transiently increased accumulation of seroma fluid in the operated inguinal region postoperatively, whereas VEGF-C did not have this side effect. Conclusions-These results show that growth factor gene therapy coupled with lymph node transfer can be used to repair damaged lymphatic networks in a large animal model and provide a basis for future clinical trials of the treatment of lymphedema.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0009-7322`
A02	`01`			`@0 CIRCAZ`
A03		`1`		`@0 Circulation : (N. Y. N.Y.)`
A05				`@2 123`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema`
A11	`01`	`1`		`@1 LÄHTEENVUO (Markku)`
A11	`02`	`1`		`@1 HONKONEN (Krista)`
A11	`03`	`1`		`@1 TERVALA (Tomi)`
A11	`04`	`1`		`@1 TAMMELA (Tuomas)`
A11	`05`	`1`		`@1 SUOMINEN (Erkki)`
A11	`06`	`1`		`@1 LÄHTEENVUO (Johanna)`
A11	`07`	`1`		`@1 KHOLOVA (Ivana)`
A11	`08`	`1`		`@1 ALITALO (Kari)`
A11	`09`	`1`		`@1 YLÄ-HERTTUALA (Seppo)`
A11	`10`	`1`		`@1 SAARISTO (Anne)`
A14	`01`			`@1 Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland @2 Kuopio @3 FIN @Z 1 aut. @Z 2 aut. @Z 6 aut. @Z 7 aut. @Z 9 aut.`
A14	`02`			`@1 Department of Plastic Surgery, Turku University Central Hospital @3 TUR @Z 3 aut. @Z 5 aut. @Z 10 aut.`
A14	`03`			`@1 Molecular/Cancer Biology Laboratory, Department of Pathology, Haartman Institute and Institute for Molecular Medicine, Biomedicum Helsinki, University of Helsinki @2 Helsinki @3 FIN @Z 4 aut. @Z 8 aut. @Z 10 aut.`
A20				`@1 613-620`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 5907 @5 354000191973680070`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 32 ref.`
A47	`01`	`1`		`@0 11-0119641`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Circulation : (New York, N.Y.)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background-Lymphedema after surgery, infection, or radiation therapy is a common and often incurable problem. Application of lymphangiogenic growth factors has been shown to induce lymphangiogenesis and to reduce tissue edema. The therapeutic effect of autologous lymph node transfer combined with adenoviral growth factor expression was evaluated in a newly established porcine model of limb lymphedema. Methods and Results-The lymphatic vasculature was destroyed within a 3-cm radius around an inguinal lymph node. Lymph node grafts and adenovirally (Ad) delivered vascular endothelial growth factor (VEGF)-C (n=5) or VEGF-D (n=9) were used to reconstruct the lymphatic network in the inguinal area; AdLacZ (β-galactosidase; n=5) served as a control. Both growth factors induced robust growth of new lymphatic vessels in the defect area, and postoperative lymphatic drainage was significantly improved in the VEGF-C/D-treated pigs compared with controls. The structure of the transferred lymph nodes was best preserved in the VEGF-C-treated pigs. Interestingly, VEGF-D transiently increased accumulation of seroma fluid in the operated inguinal region postoperatively, whereas VEGF-C did not have this side effect. Conclusions-These results show that growth factor gene therapy coupled with lymph node transfer can be used to repair damaged lymphatic networks in a large animal model and provide a basis for future clinical trials of the treatment of lymphedema.
C02	`01`	`X`		`@0 002B12B03`
C02	`02`	`X`		`@0 002B02G`
C03	`01`	`X`	`FRE`	`@0 Lymphoedème @5 01`
C03	`01`	`X`	`ENG`	`@0 Lymphedema @5 01`
C03	`01`	`X`	`SPA`	`@0 Linfedema @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 02`
C03	`02`	`X`	`ENG`	`@0 Cardiovascular disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Facteur croissance @5 09`
C03	`03`	`X`	`ENG`	`@0 Growth factor @5 09`
C03	`03`	`X`	`SPA`	`@0 Factor crecimiento @5 09`
C03	`04`	`X`	`FRE`	`@0 Traitement @5 10`
C03	`04`	`X`	`ENG`	`@0 Treatment @5 10`
C03	`04`	`X`	`SPA`	`@0 Tratamiento @5 10`
C03	`05`	`X`	`FRE`	`@0 Système autologue @5 11`
C03	`05`	`X`	`ENG`	`@0 Autologous system @5 11`
C03	`05`	`X`	`SPA`	`@0 Sistema autólogo @5 11`
C03	`06`	`X`	`FRE`	`@0 Ganglion lymphatique @5 12`
C03	`06`	`X`	`ENG`	`@0 Lymph node @5 12`
C03	`06`	`X`	`SPA`	`@0 Ganglio linfático @5 12`
C03	`07`	`X`	`FRE`	`@0 Système lymphatique @5 13`
C03	`07`	`X`	`ENG`	`@0 Lymphatic system @5 13`
C03	`07`	`X`	`SPA`	`@0 Sistema linfático @5 13`
C07	`01`	`X`	`FRE`	`@0 Pathologie des vaisseaux lymphatiques @5 37`
C07	`01`	`X`	`ENG`	`@0 Lymphatic vessel disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Linfático patología @5 37`
N21				`@1 080`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0119641 INIST
ET :	Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema
AU :	LÄHTEENVUO (Markku); HONKONEN (Krista); TERVALA (Tomi); TAMMELA (Tuomas); SUOMINEN (Erkki); LÄHTEENVUO (Johanna); KHOLOVA (Ivana); ALITALO (Kari); YLÄ-HERTTUALA (Seppo); SAARISTO (Anne)
AF :	Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland/Kuopio/Finlande (1 aut., 2 aut., 6 aut., 7 aut., 9 aut.); Department of Plastic Surgery, Turku University Central Hospital/Turquie (3 aut., 5 aut., 10 aut.); Molecular/Cancer Biology Laboratory, Department of Pathology, Haartman Institute and Institute for Molecular Medicine, Biomedicum Helsinki, University of Helsinki/Helsinki/Finlande (4 aut., 8 aut., 10 aut.)
DT :	Publication en série; Niveau analytique
SO :	Circulation : (New York, N.Y.); ISSN 0009-7322; Coden CIRCAZ; Etats-Unis; Da. 2011; Vol. 123; No. 6; Pp. 613-620; Bibl. 32 ref.
LA :	Anglais
EA :	Background-Lymphedema after surgery, infection, or radiation therapy is a common and often incurable problem. Application of lymphangiogenic growth factors has been shown to induce lymphangiogenesis and to reduce tissue edema. The therapeutic effect of autologous lymph node transfer combined with adenoviral growth factor expression was evaluated in a newly established porcine model of limb lymphedema. Methods and Results-The lymphatic vasculature was destroyed within a 3-cm radius around an inguinal lymph node. Lymph node grafts and adenovirally (Ad) delivered vascular endothelial growth factor (VEGF)-C (n=5) or VEGF-D (n=9) were used to reconstruct the lymphatic network in the inguinal area; AdLacZ (β-galactosidase; n=5) served as a control. Both growth factors induced robust growth of new lymphatic vessels in the defect area, and postoperative lymphatic drainage was significantly improved in the VEGF-C/D-treated pigs compared with controls. The structure of the transferred lymph nodes was best preserved in the VEGF-C-treated pigs. Interestingly, VEGF-D transiently increased accumulation of seroma fluid in the operated inguinal region postoperatively, whereas VEGF-C did not have this side effect. Conclusions-These results show that growth factor gene therapy coupled with lymph node transfer can be used to repair damaged lymphatic networks in a large animal model and provide a basis for future clinical trials of the treatment of lymphedema.
CC :	002B12B03; 002B02G
FD :	Lymphoedème; Pathologie de l'appareil circulatoire; Facteur croissance; Traitement; Système autologue; Ganglion lymphatique; Système lymphatique
FG :	Pathologie des vaisseaux lymphatiques
ED :	Lymphedema; Cardiovascular disease; Growth factor; Treatment; Autologous system; Lymph node; Lymphatic system
EG :	Lymphatic vessel disease
SD :	Linfedema; Aparato circulatorio patología; Factor crecimiento; Tratamiento; Sistema autólogo; Ganglio linfático; Sistema linfático
LO :	INIST-5907.354000191973680070
ID :	11-0119641

Links to Exploration step

Pascal:11-0119641

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema</title>
<author><name sortKey="L Hteenvuo, Markku" sort="L Hteenvuo, Markku" uniqKey="L Hteenvuo M" first="Markku" last="L Hteenvuo">Markku L Hteenvuo</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland</s1>
<s2>Kuopio</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Honkonen, Krista" sort="Honkonen, Krista" uniqKey="Honkonen K" first="Krista" last="Honkonen">Krista Honkonen</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland</s1>
<s2>Kuopio</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tervala, Tomi" sort="Tervala, Tomi" uniqKey="Tervala T" first="Tomi" last="Tervala">Tomi Tervala</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Plastic Surgery, Turku University Central Hospital</s1>
<s3>TUR</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tammela, Tuomas" sort="Tammela, Tuomas" uniqKey="Tammela T" first="Tuomas" last="Tammela">Tuomas Tammela</name>
<affiliation><inist:fA14 i1="03"><s1>Molecular/Cancer Biology Laboratory, Department of Pathology, Haartman Institute and Institute for Molecular Medicine, Biomedicum Helsinki, University of Helsinki</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Suominen, Erkki" sort="Suominen, Erkki" uniqKey="Suominen E" first="Erkki" last="Suominen">Erkki Suominen</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Plastic Surgery, Turku University Central Hospital</s1>
<s3>TUR</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="L Hteenvuo, Johanna" sort="L Hteenvuo, Johanna" uniqKey="L Hteenvuo J" first="Johanna" last="L Hteenvuo">Johanna L Hteenvuo</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland</s1>
<s2>Kuopio</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kholova, Ivana" sort="Kholova, Ivana" uniqKey="Kholova I" first="Ivana" last="Kholova">Ivana Kholova</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland</s1>
<s2>Kuopio</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alitalo, Kari" sort="Alitalo, Kari" uniqKey="Alitalo K" first="Kari" last="Alitalo">Kari Alitalo</name>
<affiliation><inist:fA14 i1="03"><s1>Molecular/Cancer Biology Laboratory, Department of Pathology, Haartman Institute and Institute for Molecular Medicine, Biomedicum Helsinki, University of Helsinki</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yl Herttuala, Seppo" sort="Yl Herttuala, Seppo" uniqKey="Yl Herttuala S" first="Seppo" last="Yl Herttuala">Seppo Yl Herttuala</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland</s1>
<s2>Kuopio</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saaristo, Anne" sort="Saaristo, Anne" uniqKey="Saaristo A" first="Anne" last="Saaristo">Anne Saaristo</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Plastic Surgery, Turku University Central Hospital</s1>
<s3>TUR</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Molecular/Cancer Biology Laboratory, Department of Pathology, Haartman Institute and Institute for Molecular Medicine, Biomedicum Helsinki, University of Helsinki</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0119641</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0119641 INIST</idno>
<idno type="RBID">Pascal:11-0119641</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000196</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema</title>
<author><name sortKey="L Hteenvuo, Markku" sort="L Hteenvuo, Markku" uniqKey="L Hteenvuo M" first="Markku" last="L Hteenvuo">Markku L Hteenvuo</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland</s1>
<s2>Kuopio</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Honkonen, Krista" sort="Honkonen, Krista" uniqKey="Honkonen K" first="Krista" last="Honkonen">Krista Honkonen</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland</s1>
<s2>Kuopio</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tervala, Tomi" sort="Tervala, Tomi" uniqKey="Tervala T" first="Tomi" last="Tervala">Tomi Tervala</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Plastic Surgery, Turku University Central Hospital</s1>
<s3>TUR</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tammela, Tuomas" sort="Tammela, Tuomas" uniqKey="Tammela T" first="Tuomas" last="Tammela">Tuomas Tammela</name>
<affiliation><inist:fA14 i1="03"><s1>Molecular/Cancer Biology Laboratory, Department of Pathology, Haartman Institute and Institute for Molecular Medicine, Biomedicum Helsinki, University of Helsinki</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Suominen, Erkki" sort="Suominen, Erkki" uniqKey="Suominen E" first="Erkki" last="Suominen">Erkki Suominen</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Plastic Surgery, Turku University Central Hospital</s1>
<s3>TUR</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="L Hteenvuo, Johanna" sort="L Hteenvuo, Johanna" uniqKey="L Hteenvuo J" first="Johanna" last="L Hteenvuo">Johanna L Hteenvuo</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland</s1>
<s2>Kuopio</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kholova, Ivana" sort="Kholova, Ivana" uniqKey="Kholova I" first="Ivana" last="Kholova">Ivana Kholova</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland</s1>
<s2>Kuopio</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alitalo, Kari" sort="Alitalo, Kari" uniqKey="Alitalo K" first="Kari" last="Alitalo">Kari Alitalo</name>
<affiliation><inist:fA14 i1="03"><s1>Molecular/Cancer Biology Laboratory, Department of Pathology, Haartman Institute and Institute for Molecular Medicine, Biomedicum Helsinki, University of Helsinki</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yl Herttuala, Seppo" sort="Yl Herttuala, Seppo" uniqKey="Yl Herttuala S" first="Seppo" last="Yl Herttuala">Seppo Yl Herttuala</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland</s1>
<s2>Kuopio</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saaristo, Anne" sort="Saaristo, Anne" uniqKey="Saaristo A" first="Anne" last="Saaristo">Anne Saaristo</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Plastic Surgery, Turku University Central Hospital</s1>
<s3>TUR</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Molecular/Cancer Biology Laboratory, Department of Pathology, Haartman Institute and Institute for Molecular Medicine, Biomedicum Helsinki, University of Helsinki</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Circulation : (New York, N.Y.)</title>
<title level="j" type="abbreviated">Circulation : (N. Y. N.Y.)</title>
<idno type="ISSN">0009-7322</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Circulation : (New York, N.Y.)</title>
<title level="j" type="abbreviated">Circulation : (N. Y. N.Y.)</title>
<idno type="ISSN">0009-7322</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Autologous system</term>
<term>Cardiovascular disease</term>
<term>Growth factor</term>
<term>Lymph node</term>
<term>Lymphatic system</term>
<term>Lymphedema</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lymphoedème</term>
<term>Pathologie de l'appareil circulatoire</term>
<term>Facteur croissance</term>
<term>Traitement</term>
<term>Système autologue</term>
<term>Ganglion lymphatique</term>
<term>Système lymphatique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background-Lymphedema after surgery, infection, or radiation therapy is a common and often incurable problem. Application of lymphangiogenic growth factors has been shown to induce lymphangiogenesis and to reduce tissue edema. The therapeutic effect of autologous lymph node transfer combined with adenoviral growth factor expression was evaluated in a newly established porcine model of limb lymphedema. Methods and Results-The lymphatic vasculature was destroyed within a 3-cm radius around an inguinal lymph node. Lymph node grafts and adenovirally (Ad) delivered vascular endothelial growth factor (VEGF)-C (n=5) or VEGF-D (n=9) were used to reconstruct the lymphatic network in the inguinal area; AdLacZ (β-galactosidase; n=5) served as a control. Both growth factors induced robust growth of new lymphatic vessels in the defect area, and postoperative lymphatic drainage was significantly improved in the VEGF-C/D-treated pigs compared with controls. The structure of the transferred lymph nodes was best preserved in the VEGF-C-treated pigs. Interestingly, VEGF-D transiently increased accumulation of seroma fluid in the operated inguinal region postoperatively, whereas VEGF-C did not have this side effect. Conclusions-These results show that growth factor gene therapy coupled with lymph node transfer can be used to repair damaged lymphatic networks in a large animal model and provide a basis for future clinical trials of the treatment of lymphedema.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0009-7322</s0>
</fA01>
<fA02 i1="01"><s0>CIRCAZ</s0>
</fA02>
<fA03 i2="1"><s0>Circulation : (N. Y. N.Y.)</s0>
</fA03>
<fA05><s2>123</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LÄHTEENVUO (Markku)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HONKONEN (Krista)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>TERVALA (Tomi)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>TAMMELA (Tuomas)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SUOMINEN (Erkki)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>LÄHTEENVUO (Johanna)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>KHOLOVA (Ivana)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>ALITALO (Kari)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>YLÄ-HERTTUALA (Seppo)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>SAARISTO (Anne)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland</s1>
<s2>Kuopio</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Plastic Surgery, Turku University Central Hospital</s1>
<s3>TUR</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Molecular/Cancer Biology Laboratory, Department of Pathology, Haartman Institute and Institute for Molecular Medicine, Biomedicum Helsinki, University of Helsinki</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>613-620</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>5907</s2>
<s5>354000191973680070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>32 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0119641</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Circulation : (New York, N.Y.)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background-Lymphedema after surgery, infection, or radiation therapy is a common and often incurable problem. Application of lymphangiogenic growth factors has been shown to induce lymphangiogenesis and to reduce tissue edema. The therapeutic effect of autologous lymph node transfer combined with adenoviral growth factor expression was evaluated in a newly established porcine model of limb lymphedema. Methods and Results-The lymphatic vasculature was destroyed within a 3-cm radius around an inguinal lymph node. Lymph node grafts and adenovirally (Ad) delivered vascular endothelial growth factor (VEGF)-C (n=5) or VEGF-D (n=9) were used to reconstruct the lymphatic network in the inguinal area; AdLacZ (β-galactosidase; n=5) served as a control. Both growth factors induced robust growth of new lymphatic vessels in the defect area, and postoperative lymphatic drainage was significantly improved in the VEGF-C/D-treated pigs compared with controls. The structure of the transferred lymph nodes was best preserved in the VEGF-C-treated pigs. Interestingly, VEGF-D transiently increased accumulation of seroma fluid in the operated inguinal region postoperatively, whereas VEGF-C did not have this side effect. Conclusions-These results show that growth factor gene therapy coupled with lymph node transfer can be used to repair damaged lymphatic networks in a large animal model and provide a basis for future clinical trials of the treatment of lymphedema.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B12B03</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lymphoedème</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lymphedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Linfedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Facteur croissance</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Growth factor</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Factor crecimiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Système autologue</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Autologous system</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema autólogo</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Ganglion lymphatique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Lymph node</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Ganglio linfático</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Système lymphatique</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Lymphatic system</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Sistema linfático</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie des vaisseaux lymphatiques</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Linfático patología</s0>
<s5>37</s5>
</fC07>
<fN21><s1>080</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0119641 INIST</NO>
<ET>Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema</ET>
<AU>LÄHTEENVUO (Markku); HONKONEN (Krista); TERVALA (Tomi); TAMMELA (Tuomas); SUOMINEN (Erkki); LÄHTEENVUO (Johanna); KHOLOVA (Ivana); ALITALO (Kari); YLÄ-HERTTUALA (Seppo); SAARISTO (Anne)</AU>
<AF>Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland/Kuopio/Finlande (1 aut., 2 aut., 6 aut., 7 aut., 9 aut.); Department of Plastic Surgery, Turku University Central Hospital/Turquie (3 aut., 5 aut., 10 aut.); Molecular/Cancer Biology Laboratory, Department of Pathology, Haartman Institute and Institute for Molecular Medicine, Biomedicum Helsinki, University of Helsinki/Helsinki/Finlande (4 aut., 8 aut., 10 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Circulation : (New York, N.Y.); ISSN 0009-7322; Coden CIRCAZ; Etats-Unis; Da. 2011; Vol. 123; No. 6; Pp. 613-620; Bibl. 32 ref.</SO>
<LA>Anglais</LA>
<EA>Background-Lymphedema after surgery, infection, or radiation therapy is a common and often incurable problem. Application of lymphangiogenic growth factors has been shown to induce lymphangiogenesis and to reduce tissue edema. The therapeutic effect of autologous lymph node transfer combined with adenoviral growth factor expression was evaluated in a newly established porcine model of limb lymphedema. Methods and Results-The lymphatic vasculature was destroyed within a 3-cm radius around an inguinal lymph node. Lymph node grafts and adenovirally (Ad) delivered vascular endothelial growth factor (VEGF)-C (n=5) or VEGF-D (n=9) were used to reconstruct the lymphatic network in the inguinal area; AdLacZ (β-galactosidase; n=5) served as a control. Both growth factors induced robust growth of new lymphatic vessels in the defect area, and postoperative lymphatic drainage was significantly improved in the VEGF-C/D-treated pigs compared with controls. The structure of the transferred lymph nodes was best preserved in the VEGF-C-treated pigs. Interestingly, VEGF-D transiently increased accumulation of seroma fluid in the operated inguinal region postoperatively, whereas VEGF-C did not have this side effect. Conclusions-These results show that growth factor gene therapy coupled with lymph node transfer can be used to repair damaged lymphatic networks in a large animal model and provide a basis for future clinical trials of the treatment of lymphedema.</EA>
<CC>002B12B03; 002B02G</CC>
<FD>Lymphoedème; Pathologie de l'appareil circulatoire; Facteur croissance; Traitement; Système autologue; Ganglion lymphatique; Système lymphatique</FD>
<FG>Pathologie des vaisseaux lymphatiques</FG>
<ED>Lymphedema; Cardiovascular disease; Growth factor; Treatment; Autologous system; Lymph node; Lymphatic system</ED>
<EG>Lymphatic vessel disease</EG>
<SD>Linfedema; Aparato circulatorio patología; Factor crecimiento; Tratamiento; Sistema autólogo; Ganglio linfático; Sistema linfático</SD>
<LO>INIST-5907.354000191973680070</LO>
<ID>11-0119641</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000196 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000196 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0119641
   |texte=   Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema

Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri